Rosenberg Matthew Hamilton Sells 96 Shares of Amgen Inc. (NASDAQ:AMGN)

Rosenberg Matthew Hamilton decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 10.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 816 shares of the medical research company’s stock after selling 96 shares during the period. Rosenberg Matthew Hamilton’s holdings in Amgen were worth $213,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rathbones Group PLC grew its position in shares of Amgen by 21.1% during the 2nd quarter. Rathbones Group PLC now owns 11,774 shares of the medical research company’s stock worth $3,679,000 after purchasing an additional 2,054 shares in the last quarter. Quilter Plc boosted its stake in shares of Amgen by 1.4% in the second quarter. Quilter Plc now owns 3,749 shares of the medical research company’s stock valued at $1,171,000 after buying an additional 50 shares during the period. Brown Brothers Harriman & Co. grew its position in Amgen by 21.0% during the second quarter. Brown Brothers Harriman & Co. now owns 20,452 shares of the medical research company’s stock worth $6,390,000 after buying an additional 3,555 shares in the last quarter. Fairfield Financial Advisors LTD bought a new position in Amgen during the 2nd quarter worth $2,528,000. Finally, Capital Wealth Planning LLC raised its holdings in Amgen by 47.1% in the 2nd quarter. Capital Wealth Planning LLC now owns 1,226,027 shares of the medical research company’s stock valued at $383,072,000 after acquiring an additional 392,727 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of a number of recent analyst reports. Citigroup decreased their price target on Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. Sanford C. Bernstein started coverage on shares of Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price on the stock. TD Cowen upped their price target on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Barclays lifted their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Finally, Dbs Bank upgraded Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $314.91.

Amgen Stock Up 3.0 %

Shares of NASDAQ:AMGN opened at $270.19 on Tuesday. The business has a fifty day simple moving average of $278.16 and a 200 day simple moving average of $308.35. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a market cap of $145.24 billion, a P/E ratio of 34.60, a P/E/G ratio of 2.91 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the firm earned $4.96 earnings per share. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. Analysts predict that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.52%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is currently 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.